C. Phillips

Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 Study Results

S. Vermeire, P. Higgins, J. Lindsay, 2023, Inflammatory bowel diseases.

Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1.

R. Panaccione, S. Danese, S. Schreiber, 2022, Gastroenterology & hepatology.

P370 Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from, 52-week phase, 3 study U ACHIEVE maintenance

J. Lindsay, J. Panés, Y. Sanchez Gonzalez, 2022, Journal of Crohn's and Colitis.

S773 Rapidity of Symptom Control with Upadacitinib Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Two Randomized Phase 3 Studies

S. Vermeire, Xiang Gao, E. Loftus, 2021, American Journal of Gastroenterology.

Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment.

M. Dubinsky, S. Vermeire, Xiang Gao, 2022, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Specific laboratory methodologies achieve higher model for endstage liver disease (MELD) scores for patients listed for liver transplantation

J. Trotter, B. Brimhall, R. Arjal, 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Upadacitinib Induction and Maintenance Therapy for Crohn's Disease.

G. D'Haens, Minhu Chen, L. Peyrin-Biroulet, 2023, The New England journal of medicine.

Impact of Baseline Corticosteroid Use on the Efficacy and Safety of Upadacitinib in Patients with Ulcerative Colitis: a Post Hoc Analysis of the Phase 3 Clinical Trial Programme.

T. Finney-Hayward, John Liu, C. Phillips, 2023, Journal of Crohn's & colitis.